News
AstraZeneca beat second-quarter earnings expectations on Tuesday, helped by strong sales of key cancer, heart and kidney ...
AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer ...
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.
Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...
The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...
AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...
The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...
InsideNoVa on MSN10d
AstraZeneca to build its largest-ever manufacturing facility in Virginia, creating hundreds of jobs
In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...
On July 21, AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to ...
AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...
AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...
Zacks Investment Research on MSN1d
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback